🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05871437
Starting soon Phase 4

Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier Granules

NCT05871437 · tracked via the Priya Life Science China tracker
Sponsor
Fudan University
Phase
Phase 4
Started
2025-09
Last updated
2025-09-08

Condition(s) studied

Breast Cancer

Investigational drug(s) / intervention(s)

Huaier granule →

Huaier granule: On the basis of routine clinical treatment/follow-up, take Huaier Granules orally, 10g each time, three times a day, for one year continuously or until disease progression, intolerable toxicity, withdrawal from the study for any reason or death occurs, whichever occurs first.

Study summary

This study is a prospective, multicenter, randomized controlled clinical trial designed to evaluate the rate of reduction of tumor markers to normal levels in breast cancer patients treated with Huaier granules compared to the control group.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * 18 ≤ age ≤ 75 years old, regardless of gender. * Postoperative pathological diagnosis of breast cancer. * Imaging or pathological examination without evidence of recurrence or metastasis. * If tumor markers are elevated, it is necessary to go to the corresponding department for medical treatment or issue a corresponding examination when necessary to exclude recurrence, metastasis or the second primary tumor of breast cancer. * One or more tumor markers in CEA/CA125/CA153 exceed the upper limit of normal values. * The liver and kidney functions meet the following conditions: AST and ALT\< 3 ULN, total bilirubin ≤ 2 ULN, and blood creatinine\<1.5 ULN; * Other laboratory tests meet the following requirements: Hb ≥ 9g/dl, platelet count ≥ 60 × 10\^9/L, absolute neutrophil count\>1.0 × 10\^9/L. * The patient's ECOG physical state score is 0 or 1. * The subjects participated in this study voluntarily and signed an informed consent form. Exclusion Criteria: * Diagnosed as any other malignant tumor within the 5 years prior to enrollment, except for malignant tumors with low risk of metastasis and death (5-year survival rate\>90%), such as fully treated basal cell or squamous cell skin cancer or cervical cancer in situ. * Imaging or pathological confirmation of recurrence and metastasis. * Serious infections (CTCAE\>Level 2) occurred within the first 4 weeks of enrollment, such as severe pneumonia, bacteremia, and infection complications that require hospitalization; Symptoms and signs of infection or the need for oral or intravenous antibiotic treatment within 2 weeks prior to enrollment, excluding the use of prophylactic antibiotics. * Suffering from severe acute and chronic diseases. * Suffering from severe diabetes whose blood sugar cannot be effectively controlled. * Patients who are unable to take oral medication, those who are allergic to the ingredients of Huaier granules, and pregnant or lactating women. * Drug abusers, or those who suffer from psychological or mental illnesses that may interfere with research compliance. * The researcher believes that it is not suitable to participate in this study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fudan University Shanghai Cancer Center Shanghai Shanghai Municipality

More Fudan University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05871437 on ClinicalTrials.gov ↗ ← All trials in China